Exagen (NASDAQ:XGN) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Exagen (NASDAQ:XGN) announced its earnings results on Tuesday. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02, Zacks reports. The company had revenue of $12.51 million during the quarter, compared to analysts’ expectations of $13.55 million. Exagen had a negative return on equity of 92.58% and a negative net margin of 30.36%. During the same period last year, the business posted ($0.31) EPS. Exagen updated its FY 2024 guidance to EPS.

Exagen Price Performance

NASDAQ:XGN opened at $2.90 on Friday. The stock has a fifty day moving average price of $2.83 and a 200 day moving average price of $2.37. The company has a current ratio of 4.05, a quick ratio of 4.32 and a debt-to-equity ratio of 1.54. Exagen has a 12-month low of $1.30 and a 12-month high of $3.71.

Wall Street Analysts Forecast Growth

Separately, William Blair restated an “outperform” rating on shares of Exagen in a report on Wednesday.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).